$EOLS
Evolus Inc Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000157056222000067 Filed on March 03, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$34.66M	$99.67M	$20.58M
YoY Change	68.4%	76.29%	5.81%
Cost Of Revenue	$15.83M	$43.53M	$7.280M
YoY Change	117.5%	137.9%	100.0%
Gross Profit	$18.82M	$56.14M	$13.30M
YoY Change	41.53%	46.8%	-15.88%
Gross Profit Margin	54.31%	56.32%	64.63%
Selling, General & Admin	$33.23M	$112.1M	$27.39M
YoY Change	21.34%	14.13%	-9.57%
% of Gross Profit	176.56%	199.63%	205.94%
Research & Development	$423.0K	$2.064M	$720.0K
YoY Change	-41.25%	19.86%	71.43%
% of Gross Profit	2.25%	3.68%	5.41%
Depreciation & Amortization	$920.0K	$5.622M	$1.880M
YoY Change	-51.06%	-19.99%	27.89%
% of Gross Profit	4.89%	10.01%	14.14%
Operating Expenses	$34.58M	$114.1M	$29.98M
YoY Change	15.33%	14.23%	-6.81%
Operating Profit	-$15.75M	-$44.41M	-$16.68M
YoY Change	-5.55%	-70.99%	1.96%
Interest Expense	-$140.0K	-$1.395M	-$2.820M
YoY Change	-95.04%	-85.87%	34.93%
% of Operating Profit
Other Income/Expense, Net		-$1.396M
YoY Change		-86.71%
Pretax Income	-$18.14M	-$46.77M	-$110.8M
YoY Change	-83.64%	-71.3%	657.1%
Income Tax	$42.00K	$42.00K	-$150.0K
% Of Pretax Income
Net Earnings	-$18.18M	-$46.81M	-$110.7M
YoY Change	-83.58%	-71.28%	662.85%
Net Earnings / Revenue	-52.45%	-46.96%	-537.85%
Basic Earnings Per Share		-$0.94
Diluted Earnings Per Share	-$326.7K	-$0.94	-$3.280M
COMMON SHARES
Basic Shares Outstanding	55.58M shares	49.77M shares	33.75M shares
Diluted Shares Outstanding		49.77M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$146.3M	$146.3M	$107.6M
YoY Change	35.97%	35.93%	-17.13%
Cash & Equivalents	$146.3M	$146.3M	$102.6M
Short-Term Investments	$0.00	$0.00	$5.000M
Other Short-Term Assets	$11.04M	$16.12M	$2.188M
YoY Change	404.66%	130.34%	-58.72%
Inventory	$1.762M	$1.762M	$3.354M
Prepaid Expenses	$5.082M		$4.828M
Receivables	$14.66M	$14.66M	$9.680M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$178.8M	$178.8M	$127.6M
YoY Change	40.11%	40.12%	-16.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.371M	$4.093M	$1.297M
YoY Change	5.71%	-12.91%	43.79%
Goodwill	$21.21M		$21.21M
YoY Change	0.0%		0.0%
Intangibles	$50.63M		$55.30M
YoY Change	-8.45%		-7.28%
Long-Term Investments
YoY Change
Other Assets	$2.758M	$2.758M	$240.0K
YoY Change	1049.17%	1279.0%	-90.12%
Total Long-Term Assets	$78.68M	$78.68M	$81.46M
YoY Change	-3.4%	-3.46%	-7.69%
TOTAL ASSETS
Total Short-Term Assets	$178.8M	$178.8M	$127.6M
Total Long-Term Assets	$78.68M	$78.68M	$81.46M
Total Assets	$257.5M	$257.5M	$209.1M
YoY Change	23.16%	23.14%	-13.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.091M	$6.091M	$9.615M
YoY Change	-36.65%	-36.55%	65.89%
Accrued Expenses	$29.99M	$38.32M	$9.102M
YoY Change	229.52%	-45.79%	-34.8%
Deferred Revenue	$7.934M		$3.081M
YoY Change	157.51%		80.28%
Short-Term Debt	$0.00	$0.00	$19.10M
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$0.00	$0.00	$74.40M
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$57.66M	$57.66M	$180.2M
YoY Change	-68.01%	-68.0%	637.54%
LONG-TERM LIABILITIES
Long-Term Debt	$71.22M	$71.22M	$40.50M
YoY Change	75.86%	75.86%	-44.9%
Other Long-Term Liabilities	$46.68M	$46.68M	$61.20M
YoY Change	-23.72%	-23.72%	35.7%
Total Long-Term Liabilities	$117.9M	$117.9M	$101.7M
YoY Change	15.93%	15.93%	38.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$57.66M	$57.66M	$180.2M
Total Long-Term Liabilities	$117.9M	$117.9M	$101.7M
Total Liabilities	$175.6M	$175.6M	$282.0M
YoY Change	-37.73%	-37.73%	75.19%
SHAREHOLDERS EQUITY
Retained Earnings	-$422.9M		-$376.1M
YoY Change	12.45%		76.51%
Common Stock	$1.000K		$1.000K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$81.88M	$81.88M	-$72.96M
YoY Change
Total Liabilities & Shareholders Equity	$257.5M	$257.5M	$209.1M
YoY Change	23.16%	23.14%	-13.05%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$18.18M	-$46.81M	-$110.7M
YoY Change	-83.58%	-71.28%	662.85%
Depreciation, Depletion And Amortization	$920.0K	$5.622M	$1.880M
YoY Change	-51.06%	-19.99%	27.89%
Cash From Operating Activities	-$9.044M	-$33.39M	-$2.260M
YoY Change	300.18%	-42.31%	-85.8%
INVESTING ACTIVITIES
Capital Expenditures	-$390.0K	$393.0K	-$300.0K
YoY Change	30.0%	-51.78%	-73.68%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$5.000M	$20.00M
YoY Change	-100.0%	-67.38%	32.36%
Cash From Investing Activities	-$390.0K	$4.030M	$19.70M
YoY Change	-101.98%	-66.95%	40.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	47.89M	$73.05M	0.000
YoY Change		90.5%	-100.0%
NET CHANGE
Cash From Operating Activities	-9.044M	-$33.39M	-2.260M
Cash From Investing Activities	-390.0K	$4.030M	19.70M
Cash From Financing Activities	47.89M	$73.05M	0.000
Net Change In Cash	38.46M	$43.69M	17.44M
YoY Change	120.53%	-696.1%	-75.36%
FREE CASH FLOW
Cash From Operating Activities	-$9.044M	-$33.39M	-$2.260M
Capital Expenditures	-$390.0K	$393.0K	-$300.0K
Free Cash Flow	-$8.654M	-$33.78M	-$1.960M
YoY Change	341.53%	-42.44%	-86.74%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	216000	USD
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
CY2021	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2020	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021	dei	Entity File Number EntityFileNumber	001-38381
CY2021	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1385614
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Newport Center Dr., Suite 1200
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
CY2021	dei	City Area Code CityAreaCode	949
CY2021	dei	Local Phone Number LocalPhoneNumber	284-4555
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	EOLS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q2	dei	Entity Public Float EntityPublicFloat	423200000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55694452	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Irvine, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146256000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102562000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	5000000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14657000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9680000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	1762000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3354000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5082000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4828000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	11042000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2188000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	178799000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	127612000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1371000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1297000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2722000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3414000	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50625000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	55297000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2758000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	240000	USD
CY2021Q4	us-gaap	Assets Assets	257483000	USD
CY2020Q4	us-gaap	Assets Assets	209068000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6091000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9615000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29993000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9102000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2020Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	63421000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1265000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1212000	USD
CY2021Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	5314000	USD
CY2020Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	3446000	USD
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	0	USD
CY2020Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	19068000	USD
CY2021Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	0	USD
CY2020Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	74384000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	57663000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	180248000	USD
CY2021Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	5000000	USD
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55576988	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33749228	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33749228	shares
CY2020Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	20000000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2256000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3147000	USD
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	39426000	USD
CY2020Q4	us-gaap	Contractual Obligation ContractualObligation	38100000	USD
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	71222000	USD
CY2020Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	USD
CY2020Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	40506000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	40000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	25000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	175607000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	282026000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55576988	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	504757000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	303113000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-422882000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-376072000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	81876000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-72958000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	257483000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	209068000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	99673000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	56540000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	43534000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	18299000	USD
CY2021	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	25500000	USD
CY2020	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	0	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	98190000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	112068000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2064000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1722000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-6290000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2007000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5622000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7027000	USD
CY2021	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2020	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	83421000	USD
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2020	us-gaap	Restructuring Charges RestructuringCharges	2956000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	144078000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	209608000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-44405000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-153068000	USD
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	1000	USD
CY2020	us-gaap	Investment Income Net InvestmentIncomeNet	635000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1396000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-10503000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-968000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46768000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-162936000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-46810000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-163013000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-6000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46810000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-163019000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.83
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.83
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	49773101	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49773101	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33737838	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	33737838	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	79457000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10604000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-163013000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-6000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-72958000	USD
CY2021	eols	Stock Issued During Period Values Litigation Settlement StockIssuedDuringPeriodValuesLitigationSettlement	48421000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	39808000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	655000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9638000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-46810000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	81876000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-46810000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-163013000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5622000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7027000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	9576000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	10584000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	589000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2066000	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-272000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	427000	USD
CY2021	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	692000	USD
CY2020	eols	Operating Lease Rightof Use Asset Amortization OperatingLeaseRightofUseAssetAmortization	654000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2691000	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	0	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	941000	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	506000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25000	USD
CY2021	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	6290000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-2007000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-968000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	eols	Adjustments Of Non Cash Portion Of Accrued Settlement Expenses AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses	0	USD
CY2020	eols	Adjustments Of Non Cash Portion Of Accrued Settlement Expenses AdjustmentsOfNonCashPortionOfAccruedSettlementExpenses	48421000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2979000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4542000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5566000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1085000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7264000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1690000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-787000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2320000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	20891000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4248000	USD
CY2021	eols	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	-15000000	USD
CY2020	eols	Increase Decrease In Accrued Litigation Settlement IncreaseDecreaseInAccruedLitigationSettlement	35000000	USD
CY2021	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-838000	USD
CY2020	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-734000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1497000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33388000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57871000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	393000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	815000	USD
CY2021	us-gaap	Payments For Software PaymentsForSoftware	577000	USD
CY2020	us-gaap	Payments For Software PaymentsForSoftware	2323000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4030000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	12194000	USD
CY2021	us-gaap	Repayments Of Debt RepaymentsOfDebt	76323000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	74668000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	5000000	USD
CY2020	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	90000000	USD
CY2020	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	20000000	USD
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2021	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	3097000	USD
CY2020	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	1130000	USD
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	40000000	USD
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	71958000	USD
CY2020	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	0	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	3263000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	523000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	214000	USD
CY2021	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	655000	USD
CY2020	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	73052000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	38347000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	43694000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7330000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102562000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	109892000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146256000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102562000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	138000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	7244000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	14000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	65000	USD
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	39808000	USD
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2021	eols	Stock Issued For Accrued Litigation Settlement Expense StockIssuedForAccruedLitigationSettlementExpense	48421000	USD
CY2020	eols	Stock Issued For Accrued Litigation Settlement Expense StockIssuedForAccruedLitigationSettlementExpense	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	10000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	146256000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-422882000	USD
CY2021Q2	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain comparative amounts for prior year have been reclassified to conform to current year presentations. Such reclassifications did not affect net income or retained earnings.</span></div>
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3081000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company’s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the full impact of the COVID-19 outbreak is unknown and cannot be reasonably estimated. However, where possible, management has made appropriate accounting estimates with respect to certain accounting matters, which include the fair value of royalty obligations, allowance for doubtful accounts, inventory valuation and impairment assessments of goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company’s future assessment of the magnitude and duration of the COVID-19 outbreak, as well as other factors, could result in material impacts to the Company’s financial statements in future reporting periods.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2013, Evolus and Daewoong Pharmaceutical Co. Ltd. (“Daewoong”) entered into an agreement (the “Daewoong Agreement”), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, Russia, certain members of the Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company’s business and its financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company’s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by physicians and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak and restrictions intended to slow the spread of COVID-19, including quarantines, government-mandated actions, stay-at-home orders and other restrictions, have adversely affected the Company’s business in a number of ways, which have resulted, and may continue to result, in a period of business disruption and in reduced sales and operations. In addition, any disruption and volatility in the global capital markets may increase the Company’s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company’s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company’s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7934000	USD
CY2021	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2021	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2021	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2021	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	16139000	USD
CY2020	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	16896000	USD
CY2021	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	11286000	USD
CY2020	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	15524000	USD
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2802000	USD
CY2020	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2385000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2118000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	589000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2066000	USD
CY2021	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	322000	USD
CY2020	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	335000	USD
CY2020	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	83421000	USD
CY2020	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	48421000	USD
CY2021Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	15000000	USD
CY2021	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	25500000	USD
CY2021Q4	us-gaap	Litigation Reserve Noncurrent LitigationReserveNoncurrent	5000000	USD
CY2021	us-gaap	Advertising Expense AdvertisingExpense	16391000	USD
CY2020	us-gaap	Advertising Expense AdvertisingExpense	4979000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	41546000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	44683000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	3097000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	1130000	USD
CY2021	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-6290000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	2007000	USD
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	44740000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	41546000	USD
CY2021Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	75448000	USD
CY2020Q4	us-gaap	Notes Payable Fair Value Disclosure NotesPayableFairValueDisclosure	19284000	USD
CY2020Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	76368000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	66390000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15765000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50625000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2021Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	87598000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	15765000	USD
CY2021Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	71833000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	65757000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10460000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	55297000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	21208000	USD
CY2020Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	86965000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10460000	USD
CY2020Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	76505000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3016000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3034000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2955000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2955000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2955000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	35710000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	50625000	USD
CY2021	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	633000	USD
CY2020	us-gaap	Capitalized Computer Software Additions CapitalizedComputerSoftwareAdditions	2266000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5305000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3635000	USD
CY2021Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	12447000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6856000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4076000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7934000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3081000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	595000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	895000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2161000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1050000	USD
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	29993000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9102000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	25000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	25000000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	25000000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	75000000	USD
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3778000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	71222000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2021	eols	Lessee Operating Lease Termination Period LesseeOperatingLeaseTerminationPeriod	P36M
CY2021	eols	Lessee Operating Lease Period Of Written Notice Prior To Lease Terminate Date LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate	P12M
CY2021	eols	Lessee Operating Lease Termination Fee Period Of Rent Equivalent LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent	P6M
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1065000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	1080000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	64000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	40000	USD
CY2021	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0	USD
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	168000	USD
CY2021	us-gaap	Lease Cost LeaseCost	1129000	USD
CY2020	us-gaap	Lease Cost LeaseCost	1288000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1265000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1320000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1377000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	115000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4077000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	556000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3521000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	2012000	USD
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2020Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2020Q4	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	complaint
CY2020Q4	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	2	plaintiff
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	USD
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55576988	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55576988	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.040
CY2021Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	2223080	shares
CY2020Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	1349969	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3361247	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	21000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9576000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10584000	USD
CY2021	eols	Allocated Share Based Compensation Expense Capitalized AllocatedShareBasedCompensationExpenseCapitalized	63000	USD
CY2020	eols	Allocated Share Based Compensation Expense Capitalized AllocatedShareBasedCompensationExpenseCapitalized	21000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	481000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	524000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	27000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	52000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	27000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	52000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	20000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-5000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	25000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	15000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	25000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67039000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	60083000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2839000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3938000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	2617000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	2617000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	4017000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	2559000	USD
CY2021Q4	eols	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	893000	USD
CY2020Q4	eols	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1114000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	20276000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	21318000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	85527000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	78313000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12370000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	13337000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	11528000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	12240000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	690000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12410000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	873000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	192000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	249000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	13362000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	40000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	25000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9832000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-34217000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1872000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7232000	USD
CY2021	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	1595000	USD
CY2020	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	-513000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	230000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	366000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	129000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-242000	USD
CY2021	eols	Effective Income Tax Rate Reconciliation Officers Compensation EffectiveIncomeTaxRateReconciliationOfficersCompensation	2076000	USD
CY2020	eols	Effective Income Tax Rate Reconciliation Officers Compensation EffectiveIncomeTaxRateReconciliationOfficersCompensation	133000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-17000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	616000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	147000	USD
CY2021	eols	Effective Income Tax Rate Reconciliation Promissory Note Debt Discount EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount	120000	USD
CY2020	eols	Effective Income Tax Rate Reconciliation Promissory Note Debt Discount EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount	-145000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	399000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	117000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7214000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	41341000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	42000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	77000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2924000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2761000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	163000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2924000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2924000	USD
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD

Files In Submission

Name	View Source	Status
0001570562-22-000067-index-headers.html	Edgar Link	pending
0001570562-22-000067-index.html	Edgar Link	pending
0001570562-22-000067.txt	Edgar Link	pending
0001570562-22-000067-xbrl.zip	Edgar Link	pending
eols-20211231.htm	Edgar Link	pending
eols-20211231.xsd	Edgar Link	pending
eols-20211231_cal.xml	Edgar Link	unprocessable
eols-20211231_def.xml	Edgar Link	unprocessable
eols-20211231_g1.jpg	Edgar Link	pending
eols-20211231_g2.jpg	Edgar Link	pending
eols-20211231_g3.jpg	Edgar Link	pending
eols-20211231_g4.jpg	Edgar Link	pending
eols-20211231_htm.xml	Edgar Link	completed
eols-20211231_lab.xml	Edgar Link	unprocessable
eols-20211231_pre.xml	Edgar Link	unprocessable
exhibit102012312110k.htm	Edgar Link	pending
exhibit21112312110k.htm	Edgar Link	pending
exhibit23112312110k.htm	Edgar Link	pending
exhibit31112312110k.htm	Edgar Link	pending
exhibit31212312110k.htm	Edgar Link	pending
exhibit32112312110k.htm	Edgar Link	pending
exhibit4312312110k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus Inc Stock $eols

2021 Q4 Form 10-K Financial Statement

#000157056222000067 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus Inc Stock $eols

2021 Q4 Form 10-K Financial Statement

#000157056222000067 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus Inc Stock $eols